Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1546

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Fianlimab
DRUG: Cemiplimab
DRUG: Pembrolizumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals